Zim Laboratories Upgraded to Average Quality Grade Amid Mixed Financial Performance

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a change in its quality grade from below average to average. This revision is influenced by several key financial metrics that highlight the company's performance over the past five years.
Sales growth has been recorded at 6.41%, while EBIT growth stands at a notable 23.48%. The company's EBIT to interest ratio averages at 3.42, indicating a reasonable capacity to cover interest expenses. Additionally, Zim Laboratories maintains a debt to EBITDA ratio of 2.00 and a net debt to equity ratio of 0.35, suggesting a manageable level of debt relative to its earnings and equity.

The tax ratio is reported at 32.44%, and the company has a sales to capital employed ratio of 1.29. Return on capital employed (ROCE) averages 9.39%, with return on equity (ROE) at 7.73%. Despite these metrics, Zim Laboratories has faced challenges, including negative financial performance in recent quarters and consistent underperformance against market benchmarks.

For more insights on Zim Laboratories and its financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.